BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22076473)

  • 1. PI-PLCβ1 gene copy number alterations in breast cancer.
    Molinari C; Medri L; Follo MY; Piazzi M; Mariani GA; Calistri D; Cocco L
    Oncol Rep; 2012 Feb; 27(2):403-8. PubMed ID: 22076473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
    Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
    J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
    Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
    Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
    Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
    Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer.
    Alarmo EL; Rauta J; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
    Genes Chromosomes Cancer; 2006 Apr; 45(4):411-9. PubMed ID: 16419056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
    Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
    Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR expression and gene copy number in triple-negative breast carcinoma.
    Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
    Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
    Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
    Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay.
    Bièche I; Laurendeau I; Tozlu S; Olivi M; Vidaud D; Lidereau R; Vidaud M
    Cancer Res; 1999 Jun; 59(12):2759-65. PubMed ID: 10383126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Inositide Signaling Via Phospholipase C.
    Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
    J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
    Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
    Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma.
    Parris TZ; Danielsson A; Nemes S; Kovács A; Delle U; Fallenius G; Möllerström E; Karlsson P; Helou K
    Clin Cancer Res; 2010 Aug; 16(15):3860-74. PubMed ID: 20551037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
    Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
    Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
    Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
    Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
    Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.